Printer Friendly

EMBREX'S NEW INOVOJECT SYSTEM COMPLETES SECOND PERFORMANCE SERIES

 EMBREX'S NEW INOVOJECT SYSTEM COMPLETES SECOND PERFORMANCE SERIES
 RESEARCH TRIANGLE PARK, N.C., Jan. 21 /PRNewswire/ -- The second generation Inovoject(A) egg injection system has successfully completed a second series of performance runs under commercial conditions, Embrex Inc. (NASDAQ: EMBX, EMBXW) announced today. From October through December more than 400,000 broiler chickens were vaccinated in ovo (pre-hatch) with the Inovoject system at a broiler hatchery owned by a major U.S. poultry producer. The company previously disclosed that the first series of commercial performance trials were completed in November at a hatchery owned by a different, major U.S. poultry producer.
 The performance tests compared data from Inovoject delivered Marek's vaccines, injected three days before hatch, to that from the traditional manual vaccination of chicks on day of hatch. The Inovoject vaccinated chickens had higher hatch rates and grew to greater body weights while consuming less feed.
 From the results, Embrex estimates a potential production cost savings of $100 to $130 million annually in the United States from the in ovo delivery of Marek's vaccines. The estimates are based on increased growth efficiency and reduced labor costs, and exclude Inovoject lease costs.
 Embrex estimates there are 6.5 billion broiler chickens raised in the United States annually. Worldwide, an estimated 17 billion broilers are produced each year.
 The results were released today at the International Poultry Federation meeting in Atlanta, where the second generation Inovoject system is being introduced for use by poultry producers.
 Embrex Inc. develops and has recently begun marketing bioscience and bioengineering-based products to increase the productivity and profitability of the poultry industry.
 (A) -- Registered trademark of Embrex Inc.
 -0- 1/21/92
 /CONTACT: Ken West of Embrex, 919-941-5185; or Douglas Johnson of GreenTree Communications, 800-428-8796, for Embrex/
 (EMBX) CO: Embrex Inc. ST: North Carolina, Georgia IN: FOD SU:


GK-TS -- NY014 -- 1649 01/21/92 09:04 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 21, 1992
Words:312
Previous Article:INTEGRA ANNOUNCES 1991 EARNINGS
Next Article:FIRST FIBER OPTIC TOKEN RING CONVERTER BASED ON IEEE 802.5J DRAFT STANDARDS TO BE INTRODUCED BY DU PONT AT COMNET 92 (Product Announcement)
Topics:


Related Articles
EMBREX REGISTRATION STATEMENT DECLARED EFFECTIVE
EMBREX INSTALLS INOVOJECT SYSTEM
EMBREX, INC. REPORTS RECORD FOURTH QUARTER AND FULL YEAR REVENUES
EMBREX, INC. BOARD OF DIRECTORS ADOPTS SHAREHOLDER RIGHTS PLAN
Multi-Hatchery Trials of 20 Million Broilers Show Bursaplex Improves Key Production Parameters
Embrex Names Joseph O'Dowd Director of Latin America
Embrex Second-Quarter Net Income Up 45% Due To Continued Revenue Growth
Embrex's In Ovo Vaccine, Bursaplex(TM), Receives Regulatory Approval From Thailand
Bangkok Livestock Processing Company, Ltd., Subsidiary of Charoen Pokphand Group, World's Second Largest Poultry Producer, to Install Embrex...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters